Health-related quality of life in patients with primary immunodeficiency disease by Fonda Jiang et al.
Jiang et al. Allergy Asthma Clin Immunol  (2015) 11:27 
DOI 10.1186/s13223-015-0092-y
REVIEW
Health-related quality of life in patients 
with primary immunodeficiency disease
Fonda Jiang1,3* , Troy R. Torgerson1,2 and Andrew G. Ayars1,2
Abstract 
Primary immunodeficiency disease (PIDD) with hypogammaglobulinemia is characterized by recurrent and severe 
bacterial infections and IgG replacement is the standard of care in many of these patients. Health-related quality of life 
(HRQOL) is becoming increasingly recognized as a factor that affects patient well-being and treatment preferences. In 
an effort to better understand what factors affect HRQOL in patients with PIDD, we reviewed the published litera-
ture that used standardized instruments for the measurement of HRQOL. We investigated HRQOL in PIDD patients 
compared with normal controls and patients with other chronic diseases; we also investigated the impact of treat-
ment administration on patient satisfaction. The most commonly encountered health-related quality of life instru-
ments were the child heath questionnaire parental form 50, short form 36, PedsQL 4.0, Lansky’s play performance 
scale, and Life Quality Index. Patients with PIDD scored significantly lower on many of the instruments compared with 
normal controls. Also, while it appears that many patients appreciate home-based and subcutaneous IgG replace-
ment therapy, patient satisfaction ultimately involves various clinical factors and individual patient preferences. By 
further analyzing what factors impact HRQOL, therapy adjustments can be made to maximize patient well-being and 
minimize disease impact on daily functioning.
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Background
Primary immunodeficiency disease (PIDD) is a group of 
genetic disorders characterized by increased suscepti-
bility to infection. The incidence of PIDD has increased 
markedly in the last 40  years, likely secondary to an 
expanded understanding of the genetic basis and defec-
tive immunological mechanisms responsible for PIDD 
[1–3]. The exact prevalence of PIDD is not known. Esti-
mates state 1 in 2000 children, 1 in 1200 for all persons, 
and 1 in 600 households (yielding a total population esti-
mate of between 150,000 and 360,000 persons) in the 
US are diagnosed with PIDD [1]. One survey estimates 
the most frequently occurring form of PIDD—isolated 
IgA deficiency—occurs in approximately 1 in 163 indi-
viduals in Spain [4]. PIDD can affect patients at any age 
necessitating long-term therapy with IgG replacement 
therapy.
Survival is often considered the most important out-
come in study design; however, the impact of illness 
on health-related quality of life (HRQOL) is receiv-
ing increasing recognition. HRQOL measurements are 
becoming important when analyzing not only the effect 
of the disease on patient well-being, but the satisfaction 
of patients with specific treatment regimens. Because 
many patients with PIDD require therapy indefinitely, 
the form of administration and setting where the prod-
uct is administered are important factors that can signifi-
cantly affect HRQOL. Specific measures to evaluate the 
outcome of an illness or its treatment include quantity 
and quality of life, and economic cost. The following is a 
review of the medical literature that measured HRQOL 
in PIDD patients.
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Health related quality of life (HRQOL) indicators
Outcomes of morbidity and mortality are considered 
the gold standard in most clinical studies; however, the 
impact of illness on HRQOL has received increasing 
recognition. One challenge is that HRQOL is difficult to 
conceptualize and even more difficult to measure. The 
World Health Organization defines quality of life as an 
individual’s perception of their position in life in the con-
text of the culture and value systems in which they live 
and in relation to their goals, expectations, standards 
and concerns [5]. It is a broad ranging concept affected 
by the person’s physical health, psychological state, level 
of independence, social relationships, and their relation-
ship to salient features of their environment. HRQOL 
assessments were pioneered in the field of oncology [6] 
and, more recently, immunologists have transitioned and 
employed these tools to evaluate the impact and treat-
ment of PIDD.
HRQOL assessments range from generic health sta-
tus questionnaires that are applicable to all populations 
to more specific questionnaires that evaluate particu-
lar aspects of disease or treatment modalities. Generic 
HRQOL questionnaires are usually required for stud-
ies comparing impact of a specific illness to the general 
population. An example of a generic questionnaire is the 
Short Form-36 (SF-36). This self-administered tool con-
tains 36 items and takes approximately 5  min to com-
plete. It measures 8 dimensions of health in the areas of 
functional status, well-being, and overall evaluation of 
health [7, 8]. At the other end of the spectrum are disease 
specific measurements, which are used to evaluate more 
specific aspects of disease or treatment modalities. An 
example of this instrument is the life quality index (LQI). 
Each of these tools has been used to compare intravenous 
immunoglobulin (IVIG) and subcutaneous immuno-
globulin (SCIG) therapies in PIDD patients [9, 10]. Some 
studies use a combination of these tools. Table  1 lists 
some of the most common QOL assessment tools used to 
evaluate PIDD and IgG replacement therapy.
The challenge of selecting and comparing QOL assess-
ment tools is the variation in patient populations (chil-
dren, adults, elderly, patients with comorbidities) and the 
applicability of individual tools to these specific patient 
populations. The Pediatric Quality of Life Inventory 
(PedsQL) and the Child Health Questionnaire (CHQ-
PF50) are both widely used and valid generic measures 
in children, as is the SF-36 in adults [12, 13]. In a study 
assessing the PIDD-specific LQI in comparison to the 
generic CHQ-PF50 and SF-36, it was found that related 
scales correlated well though the LQI had internal con-
sistency issues with measuring treatment costs [11]. 
There is still no universally accepted single best HRQOL 
measurement tool but continued efforts are being made 
to set quality criteria for these questionnaires [14, 15]. A 
strategy to combine generic and disease-specific meas-
ures in assessing PIDD HRQOL is ideal.
QOL in all PIDD patients
In comparison with healthy children and adults, patients 
with PIDD experience measurably lower general health 
with higher hospitalization rates and increased physi-
cal, school, and social activity limitation [11, 16–20]. 
Even compared to patients with other chronic diseases, 
patients with PIDD score lower with respect to percep-
tion of general health [19, 20]. A six-year longitudinal 
study of patients with common variable immunodefi-
ciency (CVID), a common form of PIDD, found that they 
scored lower on the General Health scale in comparison 
to other patients with chronic diseases, and that they had 
a worse perception of their general personal health and 
limitations due to their physical health [19]. This same 
study also found that PIDD patients’ QOL changed over 
time; in the 6  years between the first and final assess-
ments, a significant decline was noted in scores relating 
to bodily pain, general health, limitation due to emotional 
problems, and limitation in physical and social func-
tioning. Notably emphasizing the importance of patient 
HRQOL, this study found that patients’ relative risk 
of death, independent of age, was affected by their per-
ceived physical and social function; each point increase 
in Physical and Social functioning scores reduced the 
risk of death by 2 and 3  % respectively [19]. Another 
study comparing children with PIDD with children with 
other chronic diseases found that they generally experi-
ence similar HRQOL to patients with juvenile inflamma-
tory arthritis (JIA) but that they score lower than the JIA 
group with respect to perception of general health and 
limitations on parental time and family activities [20]. 
Mental health impacts have also been noted; children 
with PIDD found that they had significantly lower emo-
tional and social functioning compared to children with 
JIA, as well as significantly higher rates of parent-rated 
depressive and anxiety symptoms [16].
A long delay in diagnosis and a large number of infec-
tious episodes can further negatively impact HQROL 
[21] as well as lead to permanent functional impairments 
prior to initiation of treatment [22, 23]. A recent large 
scale analysis of a cohort of 2212 patients with CVID 
found that each year of diagnostic delay and each year 
of increased age at diagnosis were associated with a 1.7 
and 4.5 % increased risk of death, respectively [24]. The 
median delay in diagnosis of PIDD has decreased consid-
erably over the past 2 decades. A United States popula-
tion-based cohort study found a 17 year median delay in 
diagnosis for patients whose symptoms occurred before 
1986; this decreased to a 6.7 year median delay from 1986 
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to 1996, and decreased even further to a 2.7  year delay 
for patients whose symptoms presented after 1996 [25]. 
Despite these improvements, delayed diagnosis remains 
a significant problem [22, 26]. In a study of 32 patients 
with PIDD, more than two-thirds experienced diagnos-
tic delay, which led to serious morbidity [27]. One study 
revealed that these patients experienced two major infec-
tions requiring hospitalization that included pneumonia, 
meningitis, osteomyelitis, and septicemia during this 
time of diagnostic delay [22].
Other factors have also been noted to influence 
HRQOL in patients with PIDD; a survey of 55 patients 
≥20  years of age with PIDD found that quality of life 
scores were lowest in patients who were unemployed, 
had infections in more than four organs, had more than 
two additional diseases, and had experienced more than 
two specific occurrences of stress in the last 2–3 months 
[28]. Additionally, female gender, older age, chronic lung 
disease, and chronic diarrhea have also been shown to 
be risk factors leading to a poor quality of life in PIDD 
patients [19]. Some of the pertinent studies examining 
HRQOL in PIDD patients are summarized in Table 2.
IVIG vs no therapy
For decades, replacement therapy with IgG has been the 
therapeutic cornerstone for antibody-deficient patients 
who have recurrent infections and are deficient in total 
or specific IgG. Despite the fact that IgG replacement 
therapy is the standard of care in many patients with 
PIDD, there are limited randomized controlled trials 
comparing IgG treatment with no treatment or placebo 
due to obvious ethical concerns; similarly, there is limited 
information on mortality [29, 30]. One study of patients 
with PIDD showed the proportion of persons surviving 
10 years after diagnosis was 93.5 %, which is similar to the 
survival rate for the population at large [25]. It is known 
that IgG replacement therapy decreases the amount of 
life-threatening infections and studies have shown that 
there is a reduction in the rate of bacterial infections, 
days of antibiotic usage, days of fever, and hospital admis-
sions following IgG therapy [31–35]. Abdou et al. found 
patients on IVIG therapy had a significant improvement 
in HRQOL and reduced number of infections after com-
paring a short 3-month period without treatment with 
12  months of IVIG treatment [36]. In addition, it has 
been documented that maintaining adequate IgG levels 
can decrease infections and improve QOL [37–39].
Routes of administration‑SCIG vs IVIG
Many patients with PIDD require life-long IgG replace-
ment therapy, thus the route of administration has many 
implications on patient well-being. The first case report 
of a patient treated with IgG replacement therapy was 
in 1952 and, interestingly, this patient was treated by 
SC infusion with favorable results [40]. The use of IgG 
replacement therapy has since become the standard of 
care for patients with PIDD. For many years, IVIG ther-
apy in an outpatient setting was the treatment of choice. 
Then in the 1980s, slow SCIG infusions using portable 
syringe drivers were first introduced in the United States 
in the 1980s [41] followed by several other reports from 
the United States, Europe, and New Zealand [42]. IgG 
replacement therapy is now commonly begun by IVIG 
loading for three or more doses followed by a transi-
tion to SCIG. A large European database study included 
7350 patients with PIDD and found that though 42 % of 
patients were on IgG replacement with IVIG being the 
most common form (75.8 %), followed by SCIG (23.9 %), 
and then intramuscular immunoglobulin (IMIG) (0.3 %). 
IMIG is the least widely used due to the pain associated 
with administration [43]. A 2008 survey of patients with 
PIDD conducted by the Immune Deficiency Foundation 
had similar findings with 69 % of patients in the sample 
using IVIG and another 23 % using SCIG [44].
Though IVIG appears to be the most common form 
of IgG replacement, SCIG treatment has shown promis-
ing results. One study using SCIG loading (100  mg/kg/
day for 5 consecutive days) instead of IVIG loading at 
treatment initiation revealed that this was well-tolerated 
with no serious adverse events [45]. A recent review of 
three clinical efficacy and two extension studies found 
Hizentra®, a form of SCIG, to have comparable efficacy 
in comparison to IVIG in the prevention of serious bac-
terial infections and the maintenance of IgG levels [46]. 
Other reviews have also found that patients on SCIG 
clearly achieve acceptable IgG serum levels [37, 47] with 
minimal risk of systemic adverse events, including ana-
phylaxis [47].
A recent review of 25 studies noted that 4 studies eval-
uating health economics in SCIG and IVIG therapy all 
found SCIG to be more cost effective, mainly through the 
reduction of lost work or school days [48]. Other studies 
have shown that SCIG is more cost effective due to issues 
with IVIG such as personnel required to administer, facil-
ity rooms, administrative overheads and productivity loss 
[42, 49, 50]. In comparison to patients on IVIG, patients 
on SCIG miss significantly fewer days of work or school 
[51, 52] and one study also noted they spend significantly 
fewer days in the hospital [51]. PIDD patients’ perceived 
HRQOL are also affected by their choice of treatment 
[41, 52–54]. A Swedish study involving 25 PIDD patients, 
most of whom were on IVIG therapy, reported that ini-
tiating SCIG significantly increased their health-related 
function and improved self-rated health [54]. Similarly, 
a recent study of 50 PIDD patients shifting from IVIG 
to SCIG found that these patients subsequently had 
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a significant improvement in their total mean LQI at 
6  months that was sustained over time [52]. However, 
this same study acknowledges that it is unclear whether 
the LQI score improvement is due to the SCIG therapy 
itself, the accompanying switch to home treatments, or 
some combination of both factors. The importance of 
therapy convenience is also suggested by a past rand-
omized crossover study comparing SCIG to IVIG admin-
istration; in this study, patients on SCIG were required 
to visit the hospital more frequently than those on IVIG 
therapy (once per week in comparison to once every 
3–4 weeks) and only 10 of these 26 patients chose to con-
tinue with SCIG [55]. In fact, rather than SCIG therapy 
itself, a 3 year study in Norway noted that parents of chil-
dren with PIDD actually cited greater independence and 
the ability to stay at home as the most beneficial results of 
switching from IVIG to SCIG [53]. The review of 25 stud-
ies also noted that, though transition from hospital-based 
IVIG to home-based SCIG therapy improved HRQOL, 
this improvement seemed to be largely related to home 
therapy [48].
Home versus doctor’s office/hospital
Both SCIG and IVIG therapy are available for home 
administration, though the actual rate of use for each 
form of therapy differs. Of the PIDD patients surveyed in 
2008 by the Immune Deficiency Foundation, 42 % of the 
patients on IVIG reported that they usually received their 
infusion at home and only 7 % were able to self-infuse; in 
comparison, nearly all SCIG users (93  %) received their 
treatment at home and were able to self-infuse [44]. Mul-
tiple studies have evaluated patient preferences regarding 
IgG replacement therapy at home versus in the doctor’s 
office or hospital. In patients treated with IVIG, Daly 
et  al. found that home based IVIG improved independ-
ence, convenience and decreased disruption of activities 
[9]. Other studies have also shown that home-therapy 
regimens lead to greater improvement in HRQOL and 
treatment satisfaction [9, 11, 56, 57]. In patients treated 
with SCIG who had previously been treated with IVIG, 
Nicolay et  al. investigated the impact of weekly SCIG 
self-infusions at home on quality of life and patient satis-
faction [10, 56]. Patients who had previously been treated 
at the hospital/doctor’s office reported fewer limitations 
in their work/daily activities, significantly improved 
vitality, generally better health, and improved treat-
ment satisfaction. The preference for the SC route and 
home therapy was 81 and 90  % respectively. In patients 
who were previously treated at home with IVIG, 69 % of 
patients preferred the SC route and 92 % preferred home 
therapy [56]. In an alternate study, 73 % of adult patients 
preferred SCIG over IVIG therapy, and correspondingly 
82 % preferred home over hospital therapy; in children, 
100 % preferred both SCIG and home therapy [11]. Nota-
bly, of the patients who had previously been treated with 
IVIG home therapy but later transitioned to SCIG home 
therapy, the majority preferred SCIG therapy after 1 year.
Patients’ ability to self-administer therapy at home 
has also been shown to impact their HRQOL. The 2008 
Immune Deficiency Foundation Survey found that, while 
only 7  % of patients receiving home IVIG were able to 
self-infuse, nearly all patients receiving home SCIG were 
able to self-infuse [44]. Multiple studies have found that 
the ability to manage replacement therapy by oneself at 
home increases patient/family empowerment, makes it 
easier to work or study, improves family relations, con-
tributes to a sense of self control among patients and 
families, and improves the daily living situation [53, 58–
60]. Recently, a survey of 300 patients and caregivers of 
patients receiving IgG replacement (53 % receiving IVIG 
and 45  % receiving SCIG) found that patients and car-
egivers both preferred self-administration over adminis-
tration by a health care professional [61]. This study again 
seems to suggest that convenience plays a large role in 
patient preferences, also noting that patients prefer home 
administration, less frequent administrations of shorter 
durations, and fewer needle sticks. In a German study, 
apprehension about self-infusion and a fear of side effects 
at home were cited as the main reasons that patients 
chose to remain on IV therapy [62]. Other factors that 
play into the decision of treatment location include 
accessibility to an infusion center, the patient’s schedule 
and availability during the hours that the infusion center 
is open, reliability of the patient as assessed by the physi-
cian, ability of the patient to learn and perform the tech-
niques used in SCIG, safety, security, and cleanliness of 
the home environment, and issues related to reimburse-
ment versus out-of-pocket costs [63]. Table 3 lists factors 
that positively and negatively impact HRQOL in PIDD.
Conclusion
PIDD with significant hypogammaglobulinemia is typi-
cally characterized by recurrent and severe bacterial 
infections of the upper and lower respiratory tracts and 
is associated with poorer HRQOL than patients without 
chronic illness. Increased knowledge of specific immu-
nodeficiencies has led to a rise in the diagnosis and inci-
dence of PIDD. Since patients with PIDD often require 
life-long treatment with IgG, choices about the route of 
administration have a significant impact on HRQOL. 
Choosing the right patient, providing proper support, 
and managing expectations are key to ensuring that 
patients with PIDD achieve the maximum benefit from 
therapy.
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